Literature DB >> 8852525

Benefits and risks of torasemide in congestive heart failure and essential hypertension.

D C Brater1.   

Abstract

Torasemide is a lipophilic anilinopyridine sulphonylurea derivative that acts as a high ceiling loop diuretic and has been used for the treatment of both acute and chronic congestive heart failure (CHF) and hypertension. Torasemide is similar to other loop diuretics in terms of its mechanism of diuretic action; namely, blockade of Na+/K+/2Cl- cotransport in the thick ascending limb of the loop of Henle. It has high bioavailability (> 80%), as does bumetanide, but a longer elimination half-life (3 to 4 hours) than either bumetanide or furosemide (frusemide). In the treatment of chronic CHF, oral torasemide (5 to 20 mg/day) has been shown to be an effective diuretic. Patients treated with torasemide for up to 1 year have reduced bodyweight, improved pulmonary haemodynamics, and decreased CHF severity. Intravenous torasemide (20 to 60mg as a single dose) has been shown to be as effective as furosemide in the treatment of acute CHF, and resulted in significant diuresis, bodyweight loss, and improved pulmonary haemodynamics and exercise performance. 'Non-diuretic' dosages (2.5 to 5 mg/day) of oral torasemide have been used to treat essential hypertension, both as monotherapy and in combination with other antihypertensive agents. When used in these dosages, torasemide lowered diastolic blood pressure (DBP) to below 90mm Hg in 8 to 12 weeks in 70 to 80% of patients. With dose doubling, this level of efficacy occurred in more than 90% of hypertensive patients. Clinical trials have established that blood pressure can be maintained at this level for at least 1 year with low dose torasemide. Torasemide is well tolerated in dosages up to 20 mg/day for at least 1 year. The most commonly reported adverse effects are those associated with loop diuretics in general. These include transient hypokalaemia, hyperuricaemia, dizziness, headache, gastrointestinal disturbances, orthostatic hypotension and fatigue. Adverse effects are comparable with those of other diuretics and rarely necessitate drug withdrawal.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8852525     DOI: 10.2165/00002018-199614020-00005

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  56 in total

Review 1.  Renal and extrarenal sites of action of diuretics.

Authors:  G Giebisch; G Klein-Robbenhaar; J Klein-Robbenhaar; K Ratheiser; R Unwin
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

Review 2.  Effect of diuretics on morbidity and mortality in the treatment of hypertension.

Authors:  M Moser
Journal:  Cardiology       Date:  1994       Impact factor: 1.869

Review 3.  Clinical pharmacology of loop diuretics.

Authors:  D C Brater
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 4.  Torasemide. A review of its pharmacological properties and therapeutic potential.

Authors:  H A Friedel; M M Buckley
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

5.  Furosemide kinetics and dynamics in aged patients.

Authors:  A L Kerremans; Y Tan; H van Baars; C A van Ginneken; F W Gribnau
Journal:  Clin Pharmacol Ther       Date:  1983-08       Impact factor: 6.875

Review 6.  Diuretics and cardiovascular risk factors.

Authors:  M Moser
Journal:  Eur Heart J       Date:  1992-12       Impact factor: 29.983

7.  Symptomatic achievements with diuretics in congestive heart failure.

Authors:  A V Mattioli; E T Castellani; E Casali; G Mattioli
Journal:  Cardiology       Date:  1994       Impact factor: 1.869

Review 8.  Efficacy and tolerance of low-dose loop diuretics in hypertension.

Authors:  R E Schmieder; J K Rockstroh
Journal:  Cardiology       Date:  1994       Impact factor: 1.869

9.  Tubular effects of the diuretic torasemide.

Authors:  E Lohrmann; I Burhoff; R Greger
Journal:  Cardiology       Date:  1994       Impact factor: 1.869

10.  Anti-aldosteronergic effect of torasemide.

Authors:  T Uchida; K Yamanaga; M Nishikawa; Y Ohtaki; H Kido; M Watanabe
Journal:  Eur J Pharmacol       Date:  1991-11-26       Impact factor: 4.432

View more
  11 in total

1.  Torasemide: a pharmacoeconomic review of its use in chronic heart failure.

Authors:  M Young; G L Plosker
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 2.  Clinical pharmacokinetics and pharmacodynamics of torasemide.

Authors:  H Knauf; E Mutschler
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 3.  [Headache and hypertension. Myth and evidence].

Authors:  T Liman; E Siebert; M Endres
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

4.  Determining the effectiveness of torasemide and furosemide in heart failure: design of a randomised comparison using the regenstrief medical record system.

Authors:  M D Murray; W M Tierney; D C Brater
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 5.  Torasemide prolonged release.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2009-07-09       Impact factor: 9.546

6.  Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4.

Authors:  A A K El-Sheikh; J J M W van den Heuvel; J B Koenderink; F G M Russel
Journal:  Br J Pharmacol       Date:  2008-08-25       Impact factor: 8.739

7.  High-Dose Torasemide is Equivalent to High-Dose Furosemide with Hypertonic Saline in the Treatment of Refractory Congestive Heart Failure.

Authors:  Salvatore Paterna; Sergio Fasullo; Pietro Di Pasquale
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

8.  Safety of torasemide in healthy adult dogs administered daily for 26 weeks.

Authors:  Evelyne Coussanes; Emilie Guillot; Reynald Magnier; Anne Geneteau; Jonathan Elliott
Journal:  J Vet Pharmacol Ther       Date:  2021-11-17       Impact factor: 1.567

9.  The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial.

Authors:  Paweł Balsam; Krzysztof Ozierański; Agata Tymińska; Renata Główczyńska; Michał Peller; Anna Fojt; Andrzej Cacko; Bartosz Sieradzki; Elwira Bakuła; Maciej Markulis; Robert Kowalik; Zenon Huczek; Krzysztof J Filipiak; Grzegorz Opolski; Marcin Grabowski
Journal:  Trials       Date:  2017-01-23       Impact factor: 2.279

Review 10.  Modulation of Urate Transport by Drugs.

Authors:  Péter Tátrai; Franciska Erdő; Gabriella Dörnyei; Péter Krajcsi
Journal:  Pharmaceutics       Date:  2021-06-17       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.